Hsbc Holdings PLC Purchases 21,958 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Hsbc Holdings PLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 74.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 51,637 shares of the biopharmaceutical company’s stock after buying an additional 21,958 shares during the period. Hsbc Holdings PLC owned approximately 0.05% of Ultragenyx Pharmaceutical worth $1,080,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Leonteq Securities AG boosted its stake in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,333 shares in the last quarter. Danske Bank A S purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $39,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $56,000. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 43.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 751 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $66,000. Institutional investors own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the sale, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 19,319 shares of company stock valued at $476,837 in the last three months. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 3.4%

Shares of NASDAQ RARE opened at $25.98 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $39.89. The company has a 50 day simple moving average of $27.57 and a two-hundred day simple moving average of $24.70. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -4.25 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. During the same quarter in the previous year, the company earned ($1.57) EPS. The firm’s revenue was down 2.2% compared to the same quarter last year. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Cantor Fitzgerald upped their target price on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. Royal Bank Of Canada increased their price target on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Wells Fargo & Company boosted their price target on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Morgan Stanley upped their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $58.41.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.